RUNX1T1 and central nervous system cancer: Moreover, RUNX1T1 reportedly interacts with HIF-1α and recruits proline hydroxylase 2 (PHD2) and GSK3β for HIF-1α degradation, resulting in the inhibition of glioma cells [60] (Table 1).